Clinical trials: Juvenile Diabetes
Diabetes Type 1
A Study of LY900014 and Insulin Lispro With an External Continuous Subcutaneous Insulin Infusion System in Adult Participants With Type 1 Diabetes
The purpose of this study is to evaluate the compatibility and safety of LY900014 and insulin lispro with an external continuous subcutaneous insulin infusion system in adult participants with type 1 diabetes.
- Trial name
- PRONTO-Pump (NCT03433677)
- Testing
- LY900014, Insulin lispro
- Where
- 5 sites in United States, Spain
- Volunteers
- 49 people
- Sponsor
- Eli Lilly and Company
Type 1 Diabetes
A Study to Evaluate Safety, Engraftment, and Efficacy of VC-01 in Subjects With T1 Diabetes Mellitus
VC01-103 will evaluate an experimental combination product, cell replacement therapy intended to provide a functional cure to subjects with Type 1 Diabetes.
- Trial name
- VC01-103 (NCT04678557)
- Testing
- VC-01 Combination Product
- Where
- 4 sites in United States
- Volunteers
- 31 people
- Sponsor
- ViaCyte
Diabetic Kidney Disease, Diabetic Nephropathy
A Study in Participants With Diabetic Kidney Disease
The purpose of this study is to determine if LY2382770 is safe and effective at protecting kidney function in participants with kidney disease due to diabetes.
- Conditions
- Diabetic Kidney Disease, Diabetic Nephropathy, Diabetic Glomerulosclerosis
- Trial name
- NCT01113801
- Testing
- LY2382770
- Where
- 78 sites in United States, Australia and 5 more
- Volunteers
- 417 people
- Sponsor
- Eli Lilly and Company
Diabetes, Diabetes Mellitus, Type 1
Comparison of NN5401 Plus Insulin Aspart With Insulin Detemir Plus Insulin Aspart in Type 1 Diabetes
This trial is conducted in Europe, Oceania, and the United States of America (USA). The aim of this clinical trial is to compare NN5401 (insulin degludec/insulin aspart (IDegAsp)) with insulin detemir (IDet) plus insulin aspart…
- Trial name
- BOOST™ (NCT00978627)
- Testing
- insulin degludec/insulin aspart, insulin detemir, insulin aspart
- Where
- 81 sites in United States, Australia and 8 more
- Volunteers
- 548 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 1
Safety of Insulin Detemir Produced by a New Process as Measured by Antibody Formation in Subjects With Type 1 Diabetes
The trial was conducted in Germany, The Republic of Macedonia, Russian Federation, Serbia and South Africa. The aim of this trial was to make a safety comparison of insulin detemir produced by a new production method (NN729) with…
- Trial name
- NCT00447382
- Testing
- insulin detemir, insulin aspart
- Where
- 5 sites in Germany, North Macedonia and 3 more
- Volunteers
- 330 people
- Sponsor
- Novo Nordisk A/S
Hypoglycemia
G-Pen™ for Hypoglycemia Rescue in T1D Patients
This is an open-label, exploratory pilot study in patients with T1D. The study will involve two daytime clinical research center visits 7-14 days apart.
- Trial name
- NCT02423980
- Testing
- Glucagon
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Xeris Pharmaceuticals
Type 1 Diabetes
A Study of LY900014 and Insulin Degludec in Participants With Type 1 Diabetes
In this study, participants with type 1 diabetes (T1D) will take the study drug LY900014 and insulin degludec. The reason for this study is to evaluate the amount of time with glucose values within target range.
- Trial name
- NCT04585776
- Testing
- LY900014, Insulin Degludec
- Where
- 3 sites in United States
- Volunteers
- 31 people
- Sponsor
- Eli Lilly and Company
Diabetes, Type 1
Safety and Efficacy of Technosphere® Insulin Inhalation Powder and Lantus® Compared to Humalog® and Lantus® Over 16-Weeks
The objective of this study is to demonstrate that TI® Inhalation Powder combined with Lantus® is as effective as Humalog® combined with Lantus® on HbA1c.
- Trial name
- NCT00700622
- Testing
- Technosphere Insulin, Insulin glargine, Insulin lispro
- Where
- 22 sites in United States, Brazil
- Volunteers
- 130 people
- Sponsor
- Mannkind Corporation
Type 1 Diabetes
Clinical Trial on Ladarixin Adjunctive Therapy to Improve Glycemic Control in Type 1 Diabetes.
Primary objective To determine whether oral ladarixin versus placebo adjunctive therapy improves glycemic control in overweight, insulin resistant (IR) adult subjects with type 1 diabetes (T1D).
- Trial name
- CONSERVA (NCT05368402)
- Testing
- Ladarixin
- Where
- 2 sites in Italy
- Volunteers
- 3 people
- Sponsor
- Dompé Farmaceutici S.p.A
Type 1 Diabetes
Continuous Glucose Monitoring System (CGM)-Informed Bolus Calculator Study
Subjects will use the Omnipod Horizon™ System in Manual Mode in an outpatient setting for 14-days. Subjects will be trained to use the Manual Mode feature of the Omnipod Horizon™ System including how to use the bolus calculator…
- Trial name
- NCT04320069
- Testing
- Omnipod Horizon™ Automated Glucose Control System
- Where
- 4 sites in United States
- Volunteers
- 25 people
- Sponsor
- Insulet Corporation
Type 1 Diabetes
Control-IQ Technology for High Insulin Users With Type 1 Diabetes (Higher-IQ)
A prospective, single-arm study of 13 weeks of home use of the t:slim X2 insulin pump with Control-IQ technology in individuals with type 1 diabetes who will plan to use at least one basal rate > 3 units/hr.
- Trial name
- NCT05422053
- Testing
- t:slim X2 insulin pump with Control-IQ technology 1.5
- Where
- 4 sites in United States
- Volunteers
- 34 people
- Sponsor
- Tandem Diabetes Care, Inc.
Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
A Performance Evaluation of the Enlite Glucose Sensor to Support a Full 144 Hours(6Days) of Use
The purpose of this study is to demonstrate the performance of the Enlite Sensor over an entire calibration and wear period of 146 hours (6 days) when inserted in the abdomen and buttock and used with the Revel 2.0 Pumps in…
- Trial name
- NCT01464346
- Testing
- Enlite Sensor
- Where
- 7 sites in United States
- Volunteers
- 90 people
- Sponsor
- Medtronic MiniMed, Inc.
Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1
Long-Term Safety Study Of Inhaled Insulin (CP-464,005, Inhaler) In Japanese Patients With Type1 or Type2 Diabetes
Assess the safety and toleration of CP-464,005 and Inhaler following 1-year (52 week) administration to Type 1 and Type 2 diabetes patients (non-smokers)
- Trial name
- NCT00527397
- Testing
- CP-464,005
- Where
- 10 sites in Japan
- Volunteers
- 24 people
- Sponsor
- Pfizer
Diabetes, Type I
Efficacy & Safety of Inhaled Insulin in Type 1 Diabetes
To determine the safety and efficacy of inhaled insulin in the treatment of type 1 diabetes
- Trial name
- NCT00308308
- Testing
- Technosphere Insulin, Active comparator
- Where
- 129 sites in United States, Argentina and 8 more
- Volunteers
- 589 people, healthy volunteers welcome
- Sponsor
- Mannkind Corporation
Diabetes Mellitus, Type 1
Empagliflozin as Adjunctive to Insulin Therapy Over 26 Weeks in Patients With T1DM (EASE-3)
The study will investigate the efficacy, safety, tolerability and Pharmacokinetic(PK) of 3 doses of empagliflozin compared with placebo over 26 weeks in 960 patients with type 1 diabetes mellitus as adjunctive therapy to insulin
- Trial name
- NCT02580591
- Testing
- Empagliflozin
- Where
- 189 sites in United States, Australia and 22 more
- Volunteers
- 977 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1
The Role of Proper Insulin Injection Technique in the Treatment of Diabetes Mellitus
This is a prospective, post-marketing, single-arm clinical investigation on the effects of optimal insulin injection technique, in conjunction with the use of disposable Becton Dickinson (BD) Micro-Fine Plus 32G pen needles, by…
- Conditions
- Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1, Lipohypertrophy
- Trial name
- NCT04120974
- Testing
- Optimal insulin injection
- Where
- 4 sites in Russia
- Volunteers
- 90 people
- Sponsor
- Becton, Dickinson and Company
Diabetes Mellitus Type 1
A Prospective, Randomized, Double-blind, Placebo Controlled Study to Assess the Impact of ORMD-0801 (Insulin Capsules) on the Exogenous Insulin Requirements of Type 1 Diabetics
This will be a prospective, randomized, double-blind, placebo controlled study. Patients with established Type 1 diabetes will be eligible for entry into the study.
- Trial name
- NCT02094534
- Testing
- ORMD-0801 Capsules
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Oramed, Ltd.
Type 1 Diabetes Mellitus, Type2 Diabetes Mellitus
Performance Evaluation of an Advanced Algorithm With CGM in Adults, Adolescents, and Pediatrics
The purpose of this study is to demonstrate the performance of the Guardian™ Sensor (3) with an advanced algorithm in subjects age 2 - 80 years, for the span of 170 hours (7 days).
- Trial name
- NCT03966911
- Testing
- Guardian™ Sensor (3) connected to a Guardian™ Connect Transmitter
- Where
- 15 sites in United States
- Volunteers
- 335 people
- Sponsor
- Medtronic MiniMed, Inc.
Type 1 Diabetes Mellitus
Dapagliflozin Evaluation in Patients With Inadequately Controlled Type 1 Diabetes
The purpose of this study is to determine if adding dapagliflozin to insulin is a safe and effective therapy to improve glycemic control in patients with type 1 diabetes.
- Trial name
- DEPICT 1 (NCT02268214)
- Testing
- Dapagliflozin
- Where
- 131 sites in United States, Australia and 15 more
- Volunteers
- 833 people
- Sponsor
- AstraZeneca
Diabetes, Diabetes Mellitus, Type 1
Comparison of NN1250 With Insulin Glargine in Type 1 Diabetes
This trial is conducted in Europe and in the United States of America (USA). The aim of this trial is to investigate the efficacy and safety of NN1250 (insulin degludec) in subjects with type 1 diabetes.
- Trial name
- BEGIN™ (NCT01079234)
- Testing
- insulin degludec, insulin glargine, insulin aspart
- Where
- 82 sites in United States, Belgium and 5 more
- Volunteers
- 493 people
- Sponsor
- Novo Nordisk A/S